[
  {
    "ts": null,
    "headline": "69 May Aristocrats: Buy 1 Of 38 \"Safer\" Dividend Dogs",
    "summary": "My monthly update and commentary on changes to the S&P 500 Dividend Aristocrats, May 2025 edition. Read the full article (and which stock I recommend buying) here.",
    "url": "https://finnhub.io/api/news?id=b4bbdc6d7a7e090cba7d4f75ff7946fc39ab4b590515bfcaffe3c2ce20452b33",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747756517,
      "headline": "69 May Aristocrats: Buy 1 Of 38 \"Safer\" Dividend Dogs",
      "id": 134619568,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/486206999/image_486206999.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "My monthly update and commentary on changes to the S&P 500 Dividend Aristocrats, May 2025 edition. Read the full article (and which stock I recommend buying) here.",
      "url": "https://finnhub.io/api/news?id=b4bbdc6d7a7e090cba7d4f75ff7946fc39ab4b590515bfcaffe3c2ce20452b33"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Soared on Favorable Tailwinds",
    "summary": "Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Growth & Income Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&P 500 Index ended Q1 down 4.3%, marking a turbulent start to 2025. The volatility that began in February was triggered by factors including policy […]",
    "url": "https://finnhub.io/api/news?id=f139b8b5a63a9e0f779b74303db4a1e138db0cdee0c07359fb8b3d683dcf5ee2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747749604,
      "headline": "AbbVie (ABBV) Soared on Favorable Tailwinds",
      "id": 134628235,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Growth & Income Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&P 500 Index ended Q1 down 4.3%, marking a turbulent start to 2025. The volatility that began in February was triggered by factors including policy […]",
      "url": "https://finnhub.io/api/news?id=f139b8b5a63a9e0f779b74303db4a1e138db0cdee0c07359fb8b3d683dcf5ee2"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Signs Experimental Drug Licensing Agreement With 3SBio",
    "summary": "Pfizer inks Experimental Drug Licensing Deal With China-based company 3SBio.",
    "url": "https://finnhub.io/api/news?id=77cb96cec2117014d4256c7af043fb80ac64cdde84dead921f948f65913cf224",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747736880,
      "headline": "Pfizer Signs Experimental Drug Licensing Agreement With 3SBio",
      "id": 134609064,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Pfizer inks Experimental Drug Licensing Deal With China-based company 3SBio.",
      "url": "https://finnhub.io/api/news?id=77cb96cec2117014d4256c7af043fb80ac64cdde84dead921f948f65913cf224"
    }
  },
  {
    "ts": null,
    "headline": "Janus Henderson Global Life Sciences Diversified ADR Managed Account Q1 2025 Commentary",
    "summary": "The Portfolio returned 1.36% (gross) and the MSCI World Health Care Index SM returned 5.29%.",
    "url": "https://finnhub.io/api/news?id=62b609fa1d5756badcdc2024a29cd0511dca54f3d6b9f9baa7ca9b6096bc8b15",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747732200,
      "headline": "Janus Henderson Global Life Sciences Diversified ADR Managed Account Q1 2025 Commentary",
      "id": 134608635,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1479272648/image_1479272648.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "The Portfolio returned 1.36% (gross) and the MSCI World Health Care Index SM returned 5.29%.",
      "url": "https://finnhub.io/api/news?id=62b609fa1d5756badcdc2024a29cd0511dca54f3d6b9f9baa7ca9b6096bc8b15"
    }
  },
  {
    "ts": null,
    "headline": "Shareholders that lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) should contact Levi & Korsinsky about pending Class Action - ABBV",
    "summary": "NEW YORK, May 20, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. of a class action securities lawsuit. ...",
    "url": "https://finnhub.io/api/news?id=8fa4d91453cb24dfd04b3bd6dff406fc24f65bdfee8934b00a3533ce169fc2a7",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747719977,
      "headline": "Shareholders that lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) should contact Levi & Korsinsky about pending Class Action - ABBV",
      "id": 134606846,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "NEW YORK, May 20, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. of a class action securities lawsuit. ...",
      "url": "https://finnhub.io/api/news?id=8fa4d91453cb24dfd04b3bd6dff406fc24f65bdfee8934b00a3533ce169fc2a7"
    }
  }
]